Novo Nordisk's Pill Problem: A High-Stakes Dose of Reality

A surge in prescriptions for Novo Nordisk's new Wegovy pill is delivering a financial headache. Early data for the first quarter of 2026 shows strong patient uptake, but the mix of doses is causing analysts to slash forecasts, setting the stage for a potential earnings miss when results are published on May 6.

The core issue lies in the prescription details. Data from IQVIA indicates approximately 721,000 Wegovy pill prescriptions were written in Q1. However, a problematic 450,000 of those were for the lowest 1.5mg dosage. Priced at just $149 per month for direct purchases, this entry-level variant generates minimal revenue. Consequently, BMO Capital estimates Wegovy pill sales for the quarter at just $136 million, or about 881 million Danish kroner. This falls roughly 12% short of the market consensus, which sits near 1.001 billion kroner. In response, BMO cut its price target on Novo Nordisk shares from $45 to $36, maintaining a "Market Perform" rating.

This analyst pessimism compounds existing pressures. The competitive landscape is intensifying, with Amazon Pharmacy now offering same-day delivery for Eli Lilly's rival GLP-1 drug, Foundayo. Further price pressure comes from reports of affordable semaglutid generics emerging from India. Management itself has prepared investors for a tough year, forecasting a currency-adjusted sales decline of 5% to 13% for 2026, citing challenges like reduced Medicaid reimbursements and new pricing agreements in the key US market.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

For Novo Nordisk to bridge the revenue gap, a swift shift toward higher-dose, more expensive treatments is essential. The company has rolled out its Wegovy HD injection, a 7.2mg formulation priced around $399 monthly, nationwide in the US. Clinical trials showed patients achieving over 20% average weight loss with this high-dose therapy, positioning it as the key driver for sales growth later in the year. Analysts from UBS and others note that the Q1 report will serve as the first major test of the economics behind Novo Nordisk's new, lower price points for GLP-1 therapies.

Amid the sell-off, the company is deploying capital to signal confidence. Novo Nordisk is actively executing a share buyback program authorized for up to 15 billion kroner over twelve months. By early April, the company had already repurchased 11 million B-shares at an average price of 257.56 kroner, spending approximately 2.84 billion kroner. This tactical move comes as the stock, trading around €33.16, hovers near its 52-week low and shows a deeply oversold Relative Strength Index (RSI) reading of 19.5.

The coming weeks will determine if this internal support can counter external skepticism. All eyes are now on the early May earnings release, which will provide the definitive verdict on whether the Wegovy pill's launch is a volume success story or a profitability concern.

Ad

Novo Nordisk Stock: New Analysis - 14 April

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69145162 |